E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Bone and joint infection including; o Osteomyelitis. o Septic arthritis. o Prosthetic joint associated infection o Orthopaedic device associated infection o Discitis/ epidural abscess |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
We will compare the frequency of treatment failure with oral versus intravenous antibiotic treatment in two centres supported by a single clinical infection service. This will be needed to exclude a very marked worsening of outcome in patients on oral antibiotics. These data will be needed to justify a larger multi-centre study. |
|
E.2.2 | Secondary objectives of the trial |
To measure the nature, frequency and intensity of adverse events resulting from oral versus intravenous antibiotics. To identify the development of antibiotic resistance while on therapy or during the follow-up period. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Is willing and able to give informed consent for participation in the study. • Has a bone and joint infection* in one of the following categories; 1. Native osteomyelitis (i.e., bone infection without metalwork) where a prolonged (i.e., 6 week) course of antibiotics is indicated (i.e., excluding limited superficial disease, or patients where curative amputations or excisions of all infected bone have been carried out). 2. Native joint septic arthritis treated by excision arthoplasty, with or without intended 2-stage revision. 3. Diabetic foot infection with proven or presumptive osteomyelitis where a prolonged (i.e. 6 week) course of antibiotics is indicated (i.e., excluding limited superficial disease or patients where curative excision of all infected bone has been carried out). 4. Prosthetic joint associated infection treated by debridement and retention 5. Orthopaedic device associated infection treated by debridement and retention 6. Prosthetic joint associated infection where a 2 stage revision is planned, randomizing the patient after the 1st stage (i.e., after excision of the infected prosthesis). 7. Prosthetic joint associated infection treated by 1 stage revision 8. Removal of orthopaedic device or bone graft for infection (excluding limited superficial disease requiring short courses of antibiotics). 9. Discitis/ spinal osteomyelitis/ epidural abscess • Has had at least 48 hours, but not more than 7 days, of IV antibiotic therapy already given after definitive surgical management*. • Has a clinical diagnosis of bacterial infection (caused by any organism excepting mycobacteria). • Has a life expectancy > 1 year. • Is clinically stable in the opinion of the study clinicians, has no further interventions to treat acute infection required or planned. |
|
E.4 | Principal exclusion criteria |
• Has Staph aureus bacteraemia found on blood cultures taken for clinical indications. (No study-required blood cultures will be taken). Patients with Staph aureus bacteraemia often require longer courses of intravenous antibiotics, and may be the subject of a separate randomized trial. • Has suspected bacterial endocarditis, based on clinical, microbiological or imaging studies. (No study-required echocardiograms will be requested). Patients with endocarditis are considered to need longer courses of intravenous antibiotics. • Has suspected mediastinial infection • Has suspected central nervous system infection • Is unlikely to comply with trial requirements in the opinion of the investigator. • Has an infection for which there is no suitable antibiotic choices to permit randomization between the two arms of the trial • Has a non-bacterial (i.e., mycobacterial, fungal, parasitic or viral) infection based on clinical, histological or microbiological findings at site of infection. • Previously enrolled in the trial. • Is receiving an investigational medical product as part of another clinical trial. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint will be definite failure of infection treatment, where definite failure is indicated by one or more of the following; 1. Significant positive culture results from invasive specimens taken from the infected site, where cultures where taken for evidence of worsening infection (i.e. not taken as a matter of routine at planned surgery). 2. A positive culture result from a blood specimen taken in association with clinical signs of recurrent infection at the primary site of treatment, and where there is no other likely source of the positive blood culture (e.g., line infection, pneumonia). 3. An operative appearance of the infected site diagnostic of active infection at the time of unplanned surgery (e.g., frank pus or necrotic tissue) 4. A sinus tract at the infected site ≥3 weeks after surgical intervention.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Information not present in EudraCT |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Information not present in EudraCT |
E.7.3 | Therapeutic confirmatory (Phase III) | Information not present in EudraCT |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The last visit of the last subject. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |